Novartis AG's generic drug unit Sandoz has moved to recall generic versions of ranitidine hydrochloride in the US – the heartburn drug known by the brand name Zantac – due to contamination with a probable human carcinogen. Sandoz is the first to announce a recall in the US but more could follow as the generic drug industry once again finds itself facing a potentially widespread product contamination.
The US and EU regulatory authorities launched an investigation into the safety of ranitidine after the online pharmacy Valisure LLC...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?